NCT02922764 2025-03-26A Study of RGX-104 in Patients With Advanced Lung & Endometrial CancerInspirna, Inc.Phase 1 Completed146 enrolled
NCT03860272 2025-02-06Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerAgenus Inc.Phase 1 Active not recruiting499 enrolled
NCT03509584 2023-06-15Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer PatientsAssistance Publique Hopitaux De MarseillePhase 1 Terminated6 enrolled
NCT02381314 2022-02-08Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory CancerMacroGenicsPhase 1 Completed24 enrolled
NCT01454102 2021-10-12Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)Bristol-Myers SquibbPhase 1 Completed472 enrolled 26 charts
NCT00039091 2018-09-05Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung CancerNational Cancer Institute (NCI)Phase 1 Terminated26 enrolled
NCT01998126 2018-04-02Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung CancerUniversity of UtahPhase 1 Completed14 enrolled